Get the Stockscreener App
12.97
3.68%
0.46
Caredx Inc stock is traded at $12.97, with a volume of 1.27M.
It is up +3.68% in the last 24 hours and down -0.38% over the past month.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
See More
Previous Close:
$12.51
Open:
$12.65
24h Volume:
1.27M
Relative Volume:
0.87
Market Cap:
$690.35M
Revenue:
$312.78M
Net Income/Loss:
$-143.56M
P/E Ratio:
-4.8216
EPS:
-2.69
Net Cash Flow:
$1.22M
1W Performance:
+9.54%
1M Performance:
-0.38%
6M Performance:
-41.81%
1Y Performance:
-58.11%
1-Day Range:
$12.28
$13.04
1-Week Range:
$11.27
$13.04
52-Week Range:
$10.96
$32.97
Caredx Inc Stock (CDNA) Company Profile
Name
Caredx Inc
Sector
Industry
Phone
415-287-2300
Address
8000 MARINA BLVD, BRISBANE, CA
Compare CDNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDNA
Caredx Inc
|
12.97 | 630.74M | 312.78M | -143.56M | 1.22M | -2.69 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Caredx Inc Stock (CDNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-15-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-28-24 | Initiated | Wells Fargo | Underweight |
| Aug-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| May-13-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-09-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| Aug-15-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-11-23 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-07-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-03-23 | Downgrade | Craig Hallum | Buy → Hold |
| Mar-03-23 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Jul-20-21 | Resumed | BTIG Research | Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-26-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-30-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-08-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-02-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-26-20 | Initiated | BTIG Research | Buy |
| Jun-19-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| May-09-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-15-19 | Initiated | Jefferies | Buy |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Neutral |
| Nov-27-17 | Initiated | H.C. Wainwright | Buy |
| Jun-14-16 | Reiterated | Mizuho | Buy |
| Sep-29-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-25-15 | Initiated | Craig Hallum | Buy |
| Mar-18-15 | Reiterated | Mizuho | Buy |
View All
Caredx Inc Stock (CDNA) Latest News
The Play On CareDx (NASDAQ:CDNA) - Seeking Alpha
CareDx Inc stock momentum explainedOil Prices & Weekly Top Gainers Trade List - Newser
CareDx price target lowered to $22 from $26 at BTIG - MSN
Detecting support and resistance levels for CareDx Inc2025 Bull vs Bear & Safe Swing Trade Setups - Newser
Is a relief rally coming for CareDx Inc holdersPortfolio Risk Report & Free Fast Gain Swing Trade Alerts - Newser
How to escape a deep drawdown in CareDx IncTrade Risk Assessment & Daily Entry Point Trade Alerts - Newser
Real time alert setup for CareDx Inc performanceTrade Risk Summary & Free High Return Stock Watch Alerts - Newser
Historical volatility pattern of CareDx Inc visualized2025 Dividend Review & Daily Chart Pattern Signal Reports - Newser
How hedge fund analytics apply to CareDx Inc stockPrice Action & Daily Stock Momentum Reports - Newser
Relative strength of CareDx Inc in sector analysisWeekly Profit Analysis & High Conviction Buy Zone Alerts - Newser
Is CareDx Inc building a consolidation baseTrend Reversal & Reliable Trade Execution Plans - Newser
Forecasting CareDx Inc price range with options dataJuly 2025 Decliners & Real-Time Market Sentiment Alerts - Newser
Technical analysis overview for CareDx Inc stockJuly 2025 Recap & Technical Buy Zone Confirmations - Newser
Smart tools for monitoring CareDx Inc’s price actionQuarterly Portfolio Report & Consistent Growth Stock Picks - Newser
Should you wait for a breakout in CareDx Inc2025 Key Lessons & Weekly Top Stock Performers List - Newser
Visual analytics tools that track CareDx Inc performance2025 Sector Review & Growth Focused Stock Pick Reports - Newser
CareDx Inc’s Beta Climbs After Market VolatilityJuly 2025 Chart Watch & Short-Term High Return Strategies - metal.it
Predicting CareDx Inc trend using moving averages2025 Key Lessons & Safe Capital Allocation Plans - Newser
CareDx Inc stock trend forecastMarket Performance Summary & Reliable Volume Spike Trade Alerts - Newser
CareDx's (NASDAQ:CDNA) Earnings Aren't As Good As They Appear - Yahoo Finance
US Bancorp DE Purchases 1,235 Shares of CareDx, Inc. (NASDAQ:CDNA) - Defense World
CareDx stock price target lowered to $22 at BTIG on Medicare reimbursement concerns - Investing.com Australia
CareDx's Q2 2025 Earnings: Unpacking Contradictions in EPIC Launch, Legal Settlements, and Volume Growth - AInvest
CareDx (CDNA): Analyst Lowers Price Target, Maintains Rating | C - GuruFocus
Wells Fargo & Company Lowers CareDx (NASDAQ:CDNA) Price Target to $14.00 - Defense World
CareDx (CDNA) Price Target Cut to $14.00, Analyst Maintains 'Equal-Weight' Rating - AInvest
CareDx Reports Strong Growth in Testing Services - MSN
CareDx Inc. Reports Strong Growth Amid Challenges - The Globe and Mail
CareDx, Inc (NASDAQ:CDNA) Q2 2025 Earnings Call Transcript - Insider Monkey
CDNA’s Market Fluctuations: Is Now the Right Time to Invest? - investchronicle.com
CareDx: Wells Fargo downgrades to Equal-Weight, PT to $14 from $19. - AInvest
CareDx Q2 2025 slides: 14% revenue growth despite analyst miss, EBITDA surges - Investing.com
How CareDx Inc stock performs during market volatility300% Return Stock Forecast - classian.co.kr
CareDx (NASDAQ:CDNA) Shares Gap Down After Earnings Miss - Defense World
CareDx Publishes KOAR Study In American Journal of Transplantation, Showcasing AlloSure Dd-cfDNA For Enhanced Kidney Rejection Detection And Biopsy Guidance - 富途牛牛
CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates - MSN
CareDx Appoints New CFO Amid Financial Growth - The Globe and Mail
CareDx secretary Novack sells $34,380 in shares - Investing.com
CareDx secretary Novack sells $34,380 in shares By Investing.com - Investing.com Canada
CareDx Faces Financial Challenges Amid Mixed Signals and Policy Uncertainties - TipRanks
CareDx 2025 Q2 Earnings EPS Beats Expectations, Net Loss Widens - AInvest
CareDx shares fall 10.61% intraday after CFO changes and earnings guidance narrowing. - AInvest
CareDx narrows 2025 revenue guidance to $367M-$373M as kidney surveillance protocols expand - MSN
CareDx Names Nathan Smith as Chief Financial Officer - MarketScreener
CareDx (CDNA) EPS Beats Sales Gain 14% - sharewise.com
Earnings call transcript: CareDx Q2 2025 misses revenue forecasts By Investing.com - Investing.com Canada
Earnings call transcript: CareDx Q2 2025 misses revenue forecasts - Investing.com
CareDx Q2 2025 Earnings: EPS of -$0.10 Meets Estimates, Revenue of $90.5 Million Slightly Misses Expectations - AInvest
CareDx Publishes Landmark KOAR Study on AlloSure Efficacy in Kidney Transplant Surveillance in American Journal of Transplantation. - AInvest
CareDx: Q2 Earnings Snapshot - Greenwich Time
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer - BioSpace
Caredx Inc Stock (CDNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):